Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice

The Journal of Antimicrobial Chemotherapy
Shankaramurthy ChannabasappaBharathi Sriram

Abstract

P128 is a recombinant chimeric ectolysin with potent antistaphylococcal activity. P128 was evaluated as monotherapy and in combination with two standard-of-care (SoC) antibiotics, vancomycin and daptomycin, in mouse models of Staphylococcus aureus bacteraemia. Healthy BALB/c mice were challenged (intraperitoneally) with 109 cfu of MRSA strain COL or USA300 and treated with a single dose of P128 (0.2-10 mg/kg). Drug synergy was tested using a single dose of P128 (0.2 or 2.5 mg/kg) along with sub-therapeutic dose levels of vancomycin (27.5 or 55 mg/kg) or daptomycin (12.5 mg/kg). Bacterial load was checked in peritoneal fluid and in blood, at different time intervals. Synergy against drug-resistant strains was tested using the P128/vancomycin combination against vancomycin-resistant S. aureus (VRSA). In MRSA bacteraemia, P128, vancomycin and daptomycin monotherapy resulted in 31%, 46% and 46% survival, respectively. The P128/vancomycin and P128/daptomycin combinations afforded increased survival of 85% and 88%, respectively. P128 showed a rapid bactericidal effect with a reduction of cfu in both the peritoneal fluid and the blood within 1 h. In VRSA bacteraemia, a mouse-equivalent therapeutic dose of vancomycin (110 mg/kg) failed...Continue Reading

References

Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Nov 2, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J Liñares
Feb 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Scott K FridkinUNKNOWN Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group
Oct 27, 2004·Expert Opinion on Pharmacotherapy·Kerry L LaPlante, Michael J Rybak
Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A MangiliD H Hamer
Aug 30, 2005·Trends in Microbiology·Vincent A Fischetti
Sep 19, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marin H Kollef
Sep 13, 2007·The Journal of Antimicrobial Chemotherapy·John F Kokai-KunJames J Mond
Apr 25, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G Ralph Corey
Jun 16, 2009·Emerging Infectious Diseases·Pierre TattevinFrançoise Perdreau-Remington
Nov 17, 2009·Infectious Disease Clinics of North America·Matthew E Levison, Julie H Levison
Oct 12, 2010·Journal of Global Infectious Diseases·Poonam Sood LoombaBibhabati Mishra
Dec 24, 2010·PloS One·Guy E Thwaites, UNKNOWN United Kingdom Clinical Infection Research Group (UKCIRG)
Feb 18, 2011·Bioengineered Bugs·Mark FentonAidan Coffey
Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Abhay DhandGeorge Sakoulas
Sep 9, 2011·Current Opinion in Microbiology·Michael A Fischbach
Nov 25, 2011·Applied and Environmental Microbiology·Rotem EdgarUdi Qimron
Mar 24, 2012·BMC Microbiology·Aradhana A VipraBharathi Sriram
Jan 22, 2013·Trends in Biotechnology·Roberta J Worthington, Christian Melander
Oct 23, 2013·Antimicrobial Agents and Chemotherapy·Thomas J DilworthRenée-Claude Mercier
Dec 3, 2014·Advanced Drug Delivery Reviews·Benjamin D Brooks, Amanda E Brooks
Feb 3, 2015·Seminars in Respiratory and Critical Care Medicine·J S DavisS Y C Tong
May 29, 2015·Clinical Microbiology Reviews·Steven Y C TongVance G Fowler
Jun 1, 2017·Antimicrobial Agents and Chemotherapy·Nethravathi PoonachaUmender Sharma
Jan 13, 2018·Drug Discovery Today·Umender SharmaShankaramurthy Channabasappa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.